Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 25 September 2015, 12:19 HKT/SGT
Share:
    

Source: Eisai
Eisai to Sponsor Lectures at Japan Research Center of Fudan University in China
To promote further understanding between China and Japan as well as advance cultural exchange.

TOKYO, Sept 25, 2015 - (JCN Newswire) - Eisai Co., Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its holding company in China, Eisai China Holdings Ltd., will sponsor lectures at the Japan Research Center of Fudan University, one of China's top academic institutes, in Shanghai. Through these sponsored lectures which are mainly for students of the university, Eisai aims to foster the development of individuals who have deep understanding of the society and culture of both China and Japan, and can contribute to the further advancement of friendly locations.

Eisai to Sponsor Lectures at Japan Research Center of Fudan University in China

Established in 1905, Fudan University is a research based university that has produced many outstanding graduates not only within China but also internationally. In addition, the Japan Research Center located within the university conducts research on bilateral relations, particularly focusing on the Japanese economy, through economic, social and cultural exchange between Japan and China. Eisai helped support the establishment of the Japan Research Center in 1990.

The theme of these sponsored lectures is slated to be "Access & Innovation in the China Pharmaceutical Market." In cooperation with the Fudan University Japan Research Center, Eisai Group employees will give lectures, hold joint symposia involving Fudan University researchers and related government representatives, conduct other activities.

Furthermore, in recognition of Eisai's contributions from the establishment of the Japan Research Center until now, Fudan University conferred the honorary title of Emeritus Professor of the Fudan University Japan Research Center to Eisai Representative Corporate Officer and CEO Haruo Naito at a combined sponsorship and investiture ceremony held at the Japan Research Center on September 24, 2015.

Eisai's business in China has a history spanning almost 25 years. Eisai entered the China market in 1991 through a joint venture company, and established Eisai China Inc., a 100% wholly owned subsidiary which has a manufacturing site in Suzhou, Jiangsu province, in 1996. In addition, Eisai built a new parenteral facility in the same city in November 2014, and also determined plans for the construction of a new oral solid dose facility in February 2015 in order to further strengthen the supply chain in China. Meanwhile in December 2014, Eisai established Eisai China Holdings Ltd., a new autonomous management organization to control the China business.

Through these sponsored lectures, Eisai strives to foster individuals who are responsible for the future of the rapidly growing China pharmaceutical industry and address the diverse needs of patients and their families in China.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120



Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Apr 1, 2025 12:15 HKT/SGT
Eisai to Divest Rights for Pariet in China to Peak Pharma
Mar 25, 2025 16:28 HKT/SGT
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
Mar 25, 2025 11:21 HKT/SGT
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
Mar 10, 2025 19:24 HKT/SGT
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
Mar 5, 2025 08:09 HKT/SGT
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
Mar 4, 2025 16:22 HKT/SGT
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
Mar 3, 2025 14:41 HKT/SGT
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
Mar 3, 2025 12:53 HKT/SGT
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
Feb 28, 2025 11:31 HKT/SGT
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
Feb 20, 2025 12:29 HKT/SGT
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: